Open AccessEstablishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years
Author(s) -
Mutsa Dangarembizi,
Pearl Samson,
Edmund V. Capparelli,
Carolyn BoltonMoore,
Patrick JeanPhilippe,
Stephen A. Spector,
Nahida Chakhtoura,
Alex Benns,
Bonnie Zimmer,
Lynette Purdue,
C.D. Jackson,
Carole L. Wallis,
Jennifer Libous,
Ellen G. Chadwick
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002061
Subject(s) - efavirenz , dosing , medicine , coinfection , pharmacokinetics , pediatrics , pharmacology , human immunodeficiency virus (hiv) , viral load , immunology , antiretroviral therapy
CYP2B6 516 genotype-directed dosing improves efavirenz (EFV) exposures in HIV-infected children younger than 36 months, but such data are lacking in those with tuberculosis (TB) coinfection.